The purpose of the RECEPTOR Trial is to obtain the necessary data to enable patients and their doctors to make an evidence based decision on the first-line treatment plan for cases of discordant recurrent metastatic breast cancer.
This condition may impact as many as 50,000 people a year around the world, with a potential life expectancy impact of 1-2 years for a disease with a median life expectancy of 2-3 years. Currently, there is no clear data available to help inform the decision on the first-line treatment plan for recurrent metastatic breast cancer patients with discordant receptors.